Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent and selective small-molecule inhibitor of the Rho-associated coiled-coil containing protein kinases ROCK1 and ROCK2, with an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 under cell-free conditions (APExBIO). It demonstrates >200-fold selectivity against unrelated kinases, including PKC and MLCK. Y-27632 modulates cytoskeletal dynamics by blocking Rho-mediated stress fiber formation, enhances stem cell viability in culture, and suppresses tumor invasion and metastasis in mouse models. Its robust solubility profile and well-characterized storage conditions make it a standard reagent in workflows for cytoskeletal, cancer, and stem cell research (Mishra et al., 2024).

Biological Rationale

The Rho/ROCK signaling pathway is a central regulator of actin cytoskeleton organization, cell motility, cytokinesis, and cell cycle progression. Dysregulation of this pathway contributes to pathological processes including tumor cell invasion, metastasis, and neurodegenerative disease (Mishra et al., 2024). ROCK1 and ROCK2 are serine/threonine kinases activated downstream of the Rho family of GTPases. Selective inhibition of ROCK kinases enables targeted dissection of their roles in cell biology and disease models. Y-27632 dihydrochloride has become a benchmark tool for this purpose, allowing researchers to modulate cytoskeletal dynamics, study cell proliferation, and manipulate stem cell viability in vitro and in vivo (Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cell Models). This article extends the discussion by focusing on quantitative benchmarks and workflow integration beyond the scope of existing reviews.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a reversible, ATP-competitive inhibitor of ROCK1 and ROCK2. It binds to the catalytic domain of ROCK kinases, blocking substrate phosphorylation. The compound exhibits an IC50 of 140 nM for ROCK1, and a Ki of 300 nM for ROCK2, demonstrating >200-fold selectivity over kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK under in vitro kinase assay conditions (APExBIO). Inhibition of ROCK signaling disrupts Rho-mediated formation of stress fibers and focal adhesions, leading to cytoskeletal remodeling. Y-27632 also interferes with cell cycle progression from G1 to S phase and impairs cytokinesis, contributing to its anti-proliferative effects in certain cell types (Strategic ROCK Inhibition: Y-27632 Dihydrochloride as a Translational Tool). This article provides a quantitative update to prior mechanistic overviews by detailing selectivity and activity values under defined conditions.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM in cell-free assays (APExBIO).
• It exhibits >200-fold selectivity versus PKC, MLCK, and PAK in kinase profiling panels (APExBIO).
• Solubility is ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C (APExBIO).
• Stock solutions are stable at ≤-20°C for several months but long-term storage of solutions is not recommended (APExBIO).
• In prostatic smooth muscle cells, Y-27632 reduces proliferation in a concentration-dependent manner (10 nM–10 μM range) (APExBIO).
• In mouse tumor models, Y-27632 reduces tumor invasion and metastasis when administered systemically or locally (Mishra et al., 2024).
• In human iPSC-derived neurons and microglia, modulation of Rho/ROCK pathways impacts endosomal and lysosomal trafficking, providing a model for neurodegeneration research (Mishra et al., 2024).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used for:

• Enhancing viability and proliferation of human and mouse pluripotent stem cells during passaging and single-cell cloning (Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cell Models). This article provides updated solubility data and application limits versus the previous protocol-focused review.
• Suppression of tumor invasion and metastasis in in vivo models by targeting ROCK-mediated motility (Mishra et al., 2024).
• Dissecting cytoskeletal dynamics and cell migration in wound healing and cancer cell studies (Strategic Modulation of the Rho/ROCK Pathway: Mechanistic Insights). This article advances beyond previous reviews by emphasizing quantitative benchmarks and storage/stability data.
• Studying mechanisms of cytokinesis, cell cycle progression, and stem cell niche engineering (Y-27632 Dihydrochloride: Precision Tools for ISC Niche Engineering).

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit ROCK1/2 irreversibly; its inhibition is reversible and ATP-competitive.
• It is ineffective against kinases outside the ROCK family at concentrations <10 μM; off-target effects at higher concentrations are possible.
• Y-27632 cannot fully rescue cells from apoptosis induced by non-cytoskeletal pathways (e.g., DNA damage-induced apoptosis).
• It does not substitute for genetic knockout/knockdown of ROCK1/2 in all models, as compensatory pathways may remain active.
• Long-term storage of working solutions at room temperature leads to loss of potency; always store below -20°C and avoid freeze-thaw cycles.

Workflow Integration & Parameters

Y-27632 dihydrochloride from APExBIO (SKU: A3008) is supplied as a solid, best stored desiccated at 4°C or below. For stock solution preparation, dissolve in DMSO (recommended: 111.2 mg/mL), ethanol (17.57 mg/mL), or water (52.9 mg/mL). Solubility is enhanced by warming to 37°C or using an ultrasonic bath. For in vitro use, typical concentrations range from 1 μM to 10 μM, depending on cell type and experimental endpoint. Stock solutions should be stored at ≤-20°C for up to several months; avoid repeated freeze-thaw cycles. For in vivo applications, dosing regimens must be empirically optimized based on mouse strain, tumor model, and route of administration. Refer to Y-27632 dihydrochloride product page for detailed protocols and safety data.

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, cell-permeable, selective ROCK inhibitor, enabling precise modulation of Rho/ROCK signaling in models of cytoskeletal organization, stem cell viability, and cancer metastasis. Its robust selectivity, solubility, and defined storage parameters make it indispensable for both basic and translational research. Ongoing studies continue to expand its applications, particularly in advanced disease modeling, organoid systems, and neurodegeneration research (Mishra et al., 2024). For the latest advances in Rho/ROCK pathway modulation and best practices for deploying Y-27632 dihydrochloride in complex workflows, see Redefining Rho/ROCK Pathway Modulation: Strategic Insight. This article updates and extends previous product and protocol summaries by emphasizing quantitative selectivity benchmarks, stability data, and integration with neurodegeneration research models.